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Abstract
Background: During the Dutch Q fever epidemic more than 4,000 Q fever cases were notified. This provided logistical
challenges for the organisation of serological follow-up, which is considered mandatory for early detection of chronic
infection. The aim of this study was to investigate the proportion of acute Q fever patients that received serological follow-
up, and to identify regional differences in follow-up rates and contributing factors, such as knowledge of medical
practitioners.
Methods: Serological datasets of Q fever patients diagnosed between 2007 and 2009 (N= 3,198) were obtained from three
Laboratories of Medical Microbiology (LMM) in the province of Noord-Brabant. One LMM offered an active follow-up service
by approaching patients; the other two only tested on physician’s request. The medical microbiologist in charge of each
LMM was interviewed. In December 2011, 240 general practices and 112 medical specialists received questionnaires on their
knowledge and practices regarding the serological follow-up of Q fever patients.
Results: Ninety-five percent (2,226/2,346) of the Q fever patients diagnosed at the LMM with a follow-up service received at
least one serological follow-up within 15 months of diagnosis. For those diagnosed at a LMM without this service, this was
25% (218/852) (OR 54, 95% CI 43–67). Although 80% (162/203) of all medical practitioners with Q fever patients reported
informing patients of the importance of serological follow-up, 33% (67/203) never requested it.
Conclusions: Regional differences in follow-up are substantial and range from 25% to 95%. In areas with a low follow-up
rate the proportion of missed chronic Q fever is potentially higher than in areas with a high follow-up rate. Medical
practitioners lack knowledge regarding the need, timing and implementation of serological follow-up, which contributes to
patients receiving incorrect or no follow-up. Therefore, this information should be incorporated in national guidelines and
patient information forms.
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Introduction
In the Netherlands, more than 4,000 patients were notified with
acute Q fever during seasonal outbreaks between 2007 and 2010
[1,2]. However, at least ten times as many people might have been
infected with Coxiella burnetii in this period and had either
asymptomatic or non-diagnosed infections [3,4]. Acute Q fever
may progress to chronic Q fever in about 2% of cases [5]. Chronic
Q fever is not notifiable. There are no estimates for the proportion
of asymptomatic acute C. burnetii infections that develop into
chronic infection. The most common presentations of chronic Q
fever are endocarditis and vascular infections, conditions with high
morbidity and mortality [6]. The diagnosis of chronic Q fever is
based on clinical presentation, presence of risk factors, diagnostic
imaging techniques, detection of C. burnetii DNA in blood or tissue,
and serological test results. Detection of an IgG antibody titre
against phase I of C. burnetii of $1:1,024 in a commercially
available immunofluorescence assay during follow-up screening is
considered an important marker of chronic infection [7].
Serological follow-up of acute Q fever patients is advised in order
to identify and ensure timely treatment of chronic Q fever [8–10].
Follow-up is especially important for patients with valvulopathy,
vascular prosthesis/abnormalities, pregnant women, and immu-
nocompromised patients, as they have a higher risk of developing
chronic Q fever after acute infection [8,11].
A common but non-validated recommendation in the interna-
tional literature was to offer all patients at least two serologic tests
(at three and six months) in the first year after the diagnosis of
acute Q fever [12,13]. In 2008 the advice to test all Q fever
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patients at three, six, and twelve months after diagnosis was
published in a Dutch microbiology journal [9]. Two years later, in
2010, new advice was published in another Dutch medical journal
proposing one follow-up serologic test at nine months for low-risk
patients, while the recommendation for high-risk patients was to
test at three, six, nine, and twelve months [14]. During the Dutch
Q fever outbreak, apart from these recommendations in scientific
journal articles, there were no national guidelines on the
serological follow-up of Q fever patients.
In the province of Noord-Brabant, one Laboratory of Medical
Microbiology (LMM) used an automatic patient recall system for
the serological follow-up of patients with acute Q fever. The other
two LMMs depended on medical practitioners to request
serological Q fever follow-up. The Municipal Health Service
(MHS) Hart voor Brabant received information from both patients
and health professionals that indicated poor serological follow-up
of Q fever patients with regional differences. Therefore the
question arose, if and to what extent the serological follow-up rates
of Q fever patients differed per LMM catchment area. Are chronic
Q fever cases potentially missed due to a lack of proper follow-up?
The aim of this study was to investigate the extent to which acute
Q fever patients received serological follow-up, identify regional
differences and contributing factors and study the differences in
knowledge and practices regarding serological follow-up among
medical practitioners.
Methods
Ethics Statement
According to Dutch legislation, written consent from patients
for the use of anonymised information from laboratory databases
is not necessary, therefore ethical review was not required.
Study population and data collection
Laboratories of Medical Microbiology (LMMs). Three
LMMs (A, B, and C, see Figure 1) performed the majority of Q
fever serology in the province of Brabant. LMM-A in ’s-
Hertogenbosch provided active follow-up by contacting every
diagnosed Q fever patient for serological follow-up through an
automated system. All patients received an explanatory letter and
a laboratory form. The other two LMMs, LMM-B in Tilburg and
LMM-C in Veldhoven, performed serological follow-up only upon
request of a medical practitioner.
All three LMMs provided anonymous serological datasets from
all patients that were diagnosed with acute Q fever between
January 2007 and December 2009. Follow-up samples up to 15
months after diagnosis of Q fever were analysed for timing and
frequency. Samples that were taken within 60 days of diagnosis
were not considered as follow-up samples. Follow-up periods were
divided into 60–135 days (2–4.5 months), 136–255 days (4.5–8.5
months) and 256–450 days (8.5–15 months) in order to include the
3-, 6-, and 12-month follow-up, respectively. The 9-month follow-
up started in 2010; therefore these data are not presented as a
separate follow-up moment in this study but are included in the
follow-up period 256–450 days (8.5–15 months). Patients that were
present in the dataset of more than one LMM were only included
once by checking gender, date of birth and the postal code. These
patients were then allocated to the LMM that requested the Q
fever serology. We conducted semi-structured interviews with the
head medical microbiologist of each laboratory regarding
perceived role and responsibility of serological follow-up of Q
fever patients.
Information from general practitioners and medical
specialists
In December 2011, questionnaires were posted to all 240
general practices (with 501 general practitioners) and all internists
(N= 42), cardiologists (N= 46), and pulmonologists (N=24) from
all hospitals (N=6) in the MHS region Hart voor Brabant (MHS
HvB), the epicentre of the Q fever outbreaks (see Figure 1). We
used the term medical practitioners to refer to both general
practitioners (GPs) and medical specialists. Non-responders
received a reminder after two and four weeks. Reminders were
not sent to GPs when one out of three GPs from the medical
practice responded.
The questions posed were; work location (postal code), LMM
used, the number of Q fever patients treated and the knowledge
and practices regarding serological follow-up of Q fever patients.
Practice questions included informing the patient about the
importance of serological follow-up (never/sometimes/often/
always); requesting Q fever follow-up serology for patients
(never/sometimes/often/always); and differentiating between
high- and low-risk patient groups when offering follow-up
(never/sometimes/often/always). Never and sometimes were
regarded as inadequate practice. Knowledge questions (multiple-
choice) focused on identification of high-risk groups for developing
chronic Q fever i.e. ‘‘people with valvulopathy, vascular prosthe-
sis/abnormalities, pregnant women, and the immunocompro-
mised’’. The possibility to add another perceived risk group was
offered as an open question. The same method was used for the
follow-up, timing and differences in follow-up between high- and
low-risk group patients. Not being able to identify three high-risk
groups, and making no distinction in frequency or timing of
serological follow-up between high- and low-risk groups were
regarded as incorrect answers.
Medical practitioners were divided in groups with zero, few
(#10) and many (.10) Q fever patients and the Q fever incidence
area where they worked. These Q fever incidence areas were
based on the cumulative Q fever notification data from 2007 up to
December 2010 in the area of the MHS HvB and were defined as
low (,150 cases per 100,000 residents), medium (150–300/
100,000) and high (.300 up to 2,425/100,000) (see Figure 1).
Data analysis
All data were analysed using SPSS (v. 19) 2010. Proportions
were compared with the Mantel–Haenzel chi square and Fishers
exact test. P-values were based on two-tailed tests, defining
P,0.05 as significant.
Results
Laboratories of Medical Microbiology
We received serological datasets of 3,198 patients diagnosed by
three LMMS between 2007 and 2009 with serology indicative of
acute Q fever (Figure 1). The difference in percentage of patients
without serological follow-up within 15 months of diagnosis,
differed greatly between LMMs with an active or passive follow-up
approach (Table 1); 5% (120/2,346) versus 74% (634/852)
respectively (OR 54, 95% CI 43–67). The percentage of patients
that did not receive serological follow-up was comparable for the
two LMMs without active follow-up (74%). Overall, 24% (754/
3,198) of Q fever patients did not receive any follow-up.
During the interviews, one of the heads of an LMM (without a
follow-up service) stated that both the medical practitioner and the
MHS were responsible for the serological follow-up of Q fever
patients. The other two microbiologists perceived this to be a
shared responsibility between medical practitioners, patients, and
Regional Differences Serological Follow-Up Q Fever
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Figure 1. Cumulative Q fever incidence in the Netherlands from 2007 up to and including 2010, marking the Municipal Health
Service regions, highlighting the Municipal Health Service region Hart voor Brabant and the Laboratories of Medical Microbiology,
A in ’s-Hertogenbosch, B in Tilburg, and C in Veldhoven.
doi:10.1371/journal.pone.0060707.g001
Table 1. Diagnosis and serological follow-up up to 15 months (450 days) after diagnosis of Q fever for three Laboratories of
Medical Microbiology (LMM).
Provision follow-up service and location LMM
Yes No No Total
’s-Hertogenbosch Veldhoven Tilburg All LMM
N (%) N (%) N (%) N (%)
Total diagnosis Q-fever 2,346 (100) 527 (100) 325 (100) 3,198 (100)
Diagnosis by
GP 1,786 (76.2) 320 (60.7) 91 (28.0) 2,197 (68.7)
Specialist 536 (22.8) 207 (39.3) 137 (42.1) 880 (27.5)
Unspecified 24 (1.0) 0 (0.0) 97 (29.8) 121 (3.8)
No follow-up 120 (5.1) 392 (74.4) 242 (74.5) 754 (23.6)
Received follow-up in days after diagnosis
*60–135 2,077 (88.5) 67 (12.7) 47 (14.5) 2,191 (68.5)
136–255 2,015 (85.9) 57 (10.8) 40 (12.3) 2,112 (66.0)
256–450 1,926 (82.1) 61 (11.6) 24 (7.4) 2,011 (62.9)
Follow-up requested by
GP NA 86 (46.5) 43 (43.9) 129 (45.6)
Specialist NA 99 (53.5) 55 (56.1) 154 (54.4)
Total NA 185 (100) 98 (100){ 283 (100)
*A sample taken within 60 days after diagnosis was not considered as a follow-up sample.
{For 13 samples the applicant was unknown (request by an external laboratory).
NA: not applicable.
doi:10.1371/journal.pone.0060707.t001
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the LMM. The microbiologist in charge of LMM-A, the LMM
that provided active follow-up, chose a proactive approach at the
beginning of the outbreak. The heads of the two LMMs without
active follow-up stated that in their opinion an active recall of
patients by an LMM was not an option because they regarded this
as interfering with the responsibility of the medical practitioner.
Response questionnaires and interviews medical
practitioners
The response rate of general practices was 70% (167/240), and
included 42% (209/501) of GPs. The response rate of specialists
was 29% (32/112); highest for pulmonologists 37% (9/24) and
internists 33% (14/42), and lowest for cardiologists 15% (6/46).
The most frequently mentioned reasons for not participating in the
study by non-responders who gave reasons (N= 70) were no Q
fever patients (38%) or time constraints (25%).
Knowledge and behaviour of medical practitioners
regarding serological follow-up
Although 80% (162/203) of all medical practitioners with Q
fever patients reported informing patients of the importance of
serological follow-up, 33% (67/203) stated never to request follow-
up. Information on knowledge and practice questions for medical
practitioners with Q fever patients that do (sometimes/often/
always) offer follow-up is provided in table 2. Outcomes were
comparable for different incidence areas and type of medical
practitioner (GP or medical specialist). Medical practitioners with
one to five Q fever patients (mainly found in the low and middle
incidence areas) seemed less likely to request serological follow-up,
as 47% (27/58) stated never. There was no significant difference
compared to those with more patients. Overall, there was no
difference in reported practice of requesting follow-up serology
between GPs in an area with or without an automatic recall-
system (Table 3). GPs with many patients (.10) and working in
the catchment area of a LMM without active follow-up requested
follow-up significantly more often than those with few patients
(#10).
The ability to differentiate between high- and low-risk patient
groups was comparable for GPs and specialists. The knowledge
question; ‘‘are patients with a heart valve defect a high-risk group
for chronic Q fever’’ was answered ‘yes’ by 88% of GPs and 100%
of specialists. For stents and vascular abnormalities this was 85%
and 86%, for the immune compromised 85% and 79%, and for
pregnant during the initial infection 74% and 61%, respectively.
When looking at individual medical practitioners, 67% correctly
identified all high-risk groups. When offering serological follow-up,
35% of GPs and 22% of medical specialists never consider the risk
category of the patient. Medical practitioners with many (.10)
patients scored significantly worse for identification of the correct
high-risk groups, discussing the importance of serological follow-
up with the patient, and requesting follow-up serology for high-risk
groups (Table 2).
Both GPs (63%) and specialists (45%) assumed that the LMM
requests follow-up. GPs with few Q fever patients indicated that
they were not acquainted with the procedure and referred patients
to specialists. The main reason for not requesting serological
follow-up, mentioned by GPs with many Q fever patient cases, was
the assumption that the LMM or the MHS would take
responsibility for this.
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Discussion
Laboratory follow-up
After diagnosing acute Q fever, serologic follow-up is considered
essential for early detection and treatment of chronic Q fever.
During the Dutch Q fever outbreak there was no national
consensus nor guidelines on serological follow-up of acute Q fever
patients. In an attempt to comply with the changing recommen-
dations, LMMs and clinicians improvised. This led to an active
recall of patients by one LMM, while in other regions medical
practitioners had to organise this follow-up themselves. In this
study we analysed the outcome of these two approaches. An active
follow-up approach by a LMM led to a much higher follow-up
rate compared to follow-up by medical practitioners only (OR 54,
95% CI 43–67). When the responsibility of follow-up lies with
medical practitioners, the outcome is poor. Overall, 1,187 (37%)
patients received incomplete or no (24%; N=754) follow-up.
Ideally, the percentage of chronic Q fever cases found in the group
of patients that did receive follow-up would be known, based on
the conversion rate to chronic Q fever. However, the diagnosis of
chronic Q fever is a combination of; an IgG phase I antibody titre
against C. burnetii of $1:1,024 in immunofluorescence assay in a
follow-up sample [7], the detection of C burnetii DNA in blood or
tissue, clinical findings, the presence of risk factors, and diagnostic
imaging techniques. This additional information was unavailable.
Chronic Q fever is not notifiable and therefore we lacked accurate
data on the occurrence of chronic Q fever. We were unable to
retrieve accurate data on chronic Q fever from patients that were
lost to follow-up, as patient’s personal details were removed from
the LMM database for reasons of anonymity. We do however
know that up to the beginning of 2013 a total of 3% (71/2226) of
patients of the LMM that provided active follow-up service had an
antibody response (IgG phase I) suspect for a probable, possible or
proven chronic Q fever (personal communication, unpublished
data Nicole HM Renders, Medical Microbiologist). However, new
chronic cases are still being identified, as the average incubation
period of chronic Q fever may be long and definitive identification
and characterization of chronic Q fever patients is complicated.
Based on an estimated 1–5% conversion rate to chronic Q fever,
we calculate that approximately 12 to 59 (1–5% of 1,187 patients
without or with incomplete follow-up) chronic Q fever patients
might have been missed because of inadequate follow-up. Now
that it is known that this many traceable patients received no, or
improper follow-up, the discussion arises whether offering
serological testing years after the initial infection would be
beneficial to patients. At the same time the current screening
recommendations [14] are questioned. What percentage of
chronic Q fever might we expect to find per risk category and
how should these categories be defined? Should all 1,187 Q fever
patients need to be recalled or only a selection of high-risk
patients? What percentage of chronic Q fever patients diagnosed
several years after acute Q fever would justify such a recall?
Should one incorporate a time limit for follow-up for patients after
an acute infection that do not belong to a risk category? Other
important issues are the cut-off value of the immunofluorescence
assay, and the duration and frequency of follow-up. In the
Netherlands, several follow-up studies are currently being
conducted that may answer some of these questions.
One would assume that patient compliance is the same
regardless of the system. However, computer generated systems
are known to improve patient compliance [15] and a diagnosis of
acute Q fever made by a laboratory with an active recall-system
provides the best guarantee for receiving follow-up. The downsides
of such a system are the unnecessary exposure of patients to blood
T
a
b
le
3
.
R
e
g
io
n
al
d
if
fe
re
n
ce
s
in
re
p
o
rt
e
d
se
ro
lo
g
ic
al
fo
llo
w
-u
p
p
ra
ct
ic
e
s
b
y
G
P
s
in
re
g
io
n
s
w
it
h
a
La
b
o
ra
to
ry
o
f
M
e
d
ic
al
M
ic
ro
b
io
lo
g
y
(L
M
M
)
w
it
h
o
r
w
it
h
o
u
t
an
au
to
m
at
ic
fo
llo
w
-
u
p
sy
st
e
m
.
N
u
m
b
e
r
o
f
G
P
s
b
y
L
M
M
re
g
io
n
L
M
M
w
it
h
a
u
to
m
a
ti
c
fo
ll
o
w
u
p
;
G
P
s
N
=
1
2
3
(1
0
0
%
)
L
M
M
w
it
h
o
u
t
a
u
to
m
a
ti
c
fo
ll
o
w
-u
p
G
P
s;
N
=
4
7
(1
0
0
%
)
F
re
q
u
e
n
cy
se
ro
lo
g
y
re
q
u
e
st
G
P
F
e
w
p
a
ti
e
n
ts
#
1
0
M
a
n
y
p
a
ti
e
n
ts
.
1
0
T
o
ta
l
O
R
(9
5
%
C
I)
F
e
w
p
a
ti
e
n
ts
#
1
0
M
a
n
y
p
a
ti
e
n
ts
.
1
0
T
o
ta
l
O
R
(9
5
%
C
I)
N
(%
)
N
(%
)
N
(%
)
0
.6
(0
.2
–
1
.2
)
N
(%
)
N
(%
)
N
(%
)
4
.8
(1
.1
–
2
2
.1
)
M
o
st
ly
/a
lw
ay
s
2
3
(4
4.
2)
2
2
(3
0.
9)
4
5
(3
6.
6)
1
2
(3
2.
4)
7
(7
0.
0)
1
9
(4
0.
4)
So
m
e
ti
m
e
s/
n
e
ve
r
2
9
(5
5.
8)
4
9
(6
9.
1)
7
8
(6
3.
4)
2
5
(6
7.
6)
3
(3
0.
0)
2
8
(5
9.
6)
T
o
ta
l
5
2
(1
00
)
7
1
(1
00
)
1
2
3
(1
00
)
3
7
(1
00
)
1
0
(1
00
)
4
7
(1
00
)
M
u
n
ic
ip
al
it
ie
s
in
th
e
se
rv
ic
e
ar
e
a
o
f
a
LM
M
w
it
h
fo
llo
w
-u
p
:
H
e
u
sd
e
n
,
O
ss
,
M
aa
sd
o
n
k,
U
d
e
n
,
B
e
rn
h
e
ze
,
Li
th
,
La
n
d
e
rd
,
V
u
g
h
t,
’s
-H
e
rt
o
g
e
n
b
o
sc
h
(D
e
n
B
o
sc
h
),
Si
n
t
M
ic
h
ie
ls
g
e
st
e
l,
V
e
g
h
e
l,
Sc
h
ijn
d
e
l,
B
o
e
ke
l,
B
o
xt
e
l.
M
u
n
ic
ip
al
it
ie
s
in
th
e
se
rv
ic
e
ar
e
a
o
f
a
LM
M
w
it
h
o
u
t
fo
llo
w
-u
p
:
D
o
n
g
e
n
,
W
aa
lw
ijk
,
T
ilb
u
rg
,
O
is
te
rw
ijk
,
G
ilz
e
R
ije
n
,
Lo
o
n
o
p
Z
an
d
,
Si
n
t
O
e
d
e
n
ro
d
e
,
C
u
ijk
,
B
o
xm
e
e
r,
M
ill
e
n
Si
n
t
H
u
b
e
rt
,
H
ilv
ar
e
n
b
e
e
k,
Si
n
t
A
n
th
o
n
is
,
H
aa
re
n
,
G
ra
ve
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
6
0
7
0
7
.t
0
0
3
Regional Differences Serological Follow-Up Q Fever
PLOS ONE | www.plosone.org 5 April 2013 | Volume 8 | Issue 4 | e60707
tests and the overburdening of laboratory facilities. To prevent
overburdening, the LMM needs clinical information from the
medical practitioner to distinguish between acute and old
infections [16] and risk categories, but this information is often
not provided.
Response rate, knowledge and practices of medical
practitioners
The response rate of the general practices was good (70%), and
we consider our sample to be representative for GPs in the MHS
region as the proportions of responding practices were comparable
for the different incidence areas. We used the number of Q fever
patients per GP rather than incidence area because all GPs stated
the number of Q fever patients.
Approximately half of the medical practitioners lacked knowl-
edge on high-risk groups, distinction between low- and high-risk
patients, and the need to request serological follow-up for all acute
Q fever patients. A high proportion of medical practitioners (88%)
reported that they discussed the importance of serological follow-
up with the patient but it might be that an expected correct answer
was given [17].
Barriers to behavioural change by GPs’ and specialists’ relate to
knowledge, attitude and external factors [18,19]. Although many
different parties play a role in serological follow-up, correct
information and knowledge [18] is the first step to compliance.
During the outbreak, the MHS HvB regularly advised medical
practitioners to contact a microbiologist for specific advice on
follow-up and dispersed general information on the importance of
follow-up in update letters and in every notification report letter
(following the notification of a Q fever patient). LMM-A and
LMM-C mentioned the required serological follow-up on each Q
fever positive laboratory report while LMM-B discussed this with
the medical practitioner by telephone. The lack of knowledge
amongst medical practitioners may be due to a combination of
changing recommendations on Q fever follow-up [9,12–14]
combined with a lack of national guidelines (to this date) and
general information overload [20].
Conclusion and recommendations
The serological follow-up of Q fever patients poses logistical
challenges. Our results clearly indicate that a LMM based follow-
up system with active patient approach achieves high patient
compliance compared with systems that rely on referral by
medical practitioners. Also, the current registration systems of
medical practitioners are not suited to follow-up Q fever patients.
Medical practitioners hold others, including the patient, respon-
sible for follow-up and often lack knowledge on the indication for
and implementation of serological follow-up of Q fever. A lesson
learned from this outbreak, is that recommendations on best
practices regarding the serological follow-up of acute Q fever
patients should be translated into practical guidelines for medical
practitioners early on during an outbreak. The recommendation
on serological follow-up should also be incorporated in patient
information leaflets. Recalling selected high risk patients that
received incomplete or no serological follow-up should be
considered. Additional information, on conversion to chronic Q
fever per patient category in time, is needed in order to decide
which patient groups should be recalled and up to what time after
initial infection. Organising such a recall needs to be a joint action
by medical practitioners, the LMM, the Q fever patient
association and the MHS.
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